Don’t even think about buying Canopy Growth stock until you read this brutal reality check
Canopy Growth is a penny stock for a reason, so only the most aggressive investors should even be looking at it.
Don’t even think about buying Tilray stock until you read this warning
Tilray is moving in the right direction, but it still isn’t a sustainably profitable business.
4 Things You Need to Know If You’re Thinking of Buying Innovative Industrial Properties Today
If you’re thinking about buying this beaten-down stock ahead of that report, here are four key factors to consider. Innovative Industrial Properties had a disappointing Q3. Revenue fell 15.4% year …
Canopy Growth or Tilray Brands: Which Stock Is More Likely to Be a Millionaire Maker?
Both companies have positioned themselves to capitalize on potential opportunities in the cannabis market. However, there is significant uncertainty ahead, due to regulatory issues (and other concerns …
SNDL stock loses 31% in six months: Should you buy the dip?
Shares of SNDL Inc. SNDL, one of the largest vertically integrated cannabis players in Canada, have been declining steadily over the past six months. This pullback does not stem from company-specific …
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
This cannabis stock will beat the market, analyst says
Haywood Capital Markets analyst Neal Gilmer has reiterated his “Buy” rating and $1.30 target price on Rubicon Organics …
Debt dominates cannabis capital raises as equity deals dry up
The cannabis industry has transitioned to a more commoditized market characterized by price declines and minimal organic growth.
1 stock I’d buy today, 1 I wouldn’t touch
Investing is about picking the right stocks and avoiding the wrong ones. While some companies are capitalizing on powerful trends, others continue to struggle despite industry tailwinds. Before I dive …
Cannabis biz could list on stock exchanges under new congressional bill (Newsletter: March 20, 2026)
THC in Medicare CBD coverage plan; Marijuana bills on VA gov’s desk; IA psilocybin; Study: Cannabis safer than alcohol & tobacco Subscribe to receive Marijuana Moment’s newsletter in your inbox every …
Is Tilray stock going to $0?
The company isn’t in good financial shape, and there’s still plenty of risk with the stock.
This Canadian cannabis stock is a buy, analyst says
Research Capital analyst Andre Greg McLeish has reiterated a “Buy” rating and $3.50 price target on Cannara Biotech …
Should you sell your Aurora Cannabis stock?
Roth Capital Markets analyst Bill Kirk reiterated a “Neutral” rating on ACB and lowered his 12-month price target to C$5.00 from C$6.00 …
Should you buy, hold or sell ACB stock post Q3 earnings release?
Aurora Cannabis ACB recently reported its third-quarter results for fiscal 2026 (year ending March 2026). Both earnings and sales beat our consensus estimates. This Canada-based cannabis operator …
Aurora Cannabis Reports Increased Revenue And Free Cash Flow For Q3-2026
Aurora Cannabis Inc. Q3 results: revenue, free cash flow up as ACB exits propagation & targets higher-margin international medical cannabis. Click for this update.
Recent Comments